Bausch Health Companies  logo
Bausch Health Companies BHC
$ 6.95 -0.93%

Quarterly report 2024-Q2
added 08-01-2024

report update icon

Bausch Health Companies General and Administrative Expenses 2011-2025 | BHC

General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.
What these expenses include
  • Salaries of administrative staff (executives, HR, accountants, legal personnel)
  • Office rent and utilities
  • Office equipment and IT infrastructure
  • Professional services (auditors, lawyers, consultants)
  • Insurance
  • General administrative travel and representation expenses
What the metric indicates
  • Cost control
    A high level of such expenses may indicate inefficient management or an overly complex structure
  • Profitability
    Reducing administrative expenses while maintaining stable revenue increases operating profit
  • Comparative analysis
    Investors can compare this metric as a percentage of revenue among companies in the same industry
  • Business flexibility
    Companies with a flexible and controlled expense structure are more resilient to revenue declines

Annual General and Administrative Expenses Bausch Health Companies

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
2.92 B 2.62 B 2.62 B 2.37 B 2.55 B 2.47 B 2.58 B 2.81 B 2.7 B 2.03 B 1.31 B 813 M 584 M

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
2.92 B 584 M 2.18 B

Quarterly General and Administrative Expenses Bausch Health Companies

2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
832 M 794 M - 715 M 711 M 725 M - 661 M 676 M 622 M - 653 M 685 M 606 M - 572 M 526 M 633 M - 648 M 651 M 587 M - 614 M 642 M 591 M - 623 M 659 M 661 M - 661 M 671 M 813 M - 698 M 686 M 574 M - 504 M 516 M 482 M - 356 M 257 M 242 M - 189 M 185 M 177 M - 135 M 150 M 140 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
832 M 135 M 549 M

General and Administrative Expenses of other stocks in the Drug manufacturers industry

Issuer General and Administrative Expenses Price % 24h Market Cap Country
Alimera Sciences Alimera Sciences
ALIM
18.5 M - - $ 142 M usaUSA
Canopy Growth Corporation Canopy Growth Corporation
CGC
170 M $ 1.7 50.0 % $ 183 M canadaCanada
Aerie Pharmaceuticals Aerie Pharmaceuticals
AERI
138 M - - $ 754 M usaUSA
Cronos Group Cronos Group
CRON
95.9 M $ 3.24 13.51 % $ 1.69 B canadaCanada
Assertio Holdings Assertio Holdings
ASRT
78.6 M $ 0.77 -1.79 % $ 54.7 M usaUSA
AcelRx Pharmaceuticals AcelRx Pharmaceuticals
ACRX
8.53 M - 7.5 % $ 6.35 M usaUSA
Adamis Pharmaceuticals Corporation Adamis Pharmaceuticals Corporation
ADMP
13.2 M - 0.86 % $ 117 M usaUSA
Agile Therapeutics Agile Therapeutics
AGRX
10.5 M - 10.11 % $ 58.2 M usaUSA
Aurora Cannabis Aurora Cannabis
ACB
119 M $ 5.36 17.8 % $ 86.3 M canadaCanada
Catalent Catalent
CTLT
935 M - - $ 11.5 B usaUSA
Calliditas Therapeutics AB (publ) Calliditas Therapeutics AB (publ)
CALT
390 M - -0.1 % $ 2.03 B schwedenSchweden
HEXO Corp. HEXO Corp.
HEXO
58.2 M - 2.45 % $ 38.1 M canadaCanada
DURECT Corporation DURECT Corporation
DRRX
14.4 M - - $ 50.1 M usaUSA
Eagle Pharmaceuticals Eagle Pharmaceuticals
EGRX
107 M - -39.89 % $ 27.7 M usaUSA
Endo International plc Endo International plc
ENDP
568 M - - $ 28.9 M irlandaIrlanda
Emergent BioSolutions Emergent BioSolutions
EBS
368 M $ 11.46 -2.22 % $ 587 M usaUSA
Evoke Pharma Evoke Pharma
EVOK
12.2 M $ 10.97 0.18 % $ 36.7 M usaUSA
Athenex Athenex
ATNX
44.9 M - -23.39 % $ 1.76 M usaUSA
Avadel Pharmaceuticals plc Avadel Pharmaceuticals plc
AVDL
181 M $ 21.38 -0.05 % $ 2.03 B franceFrance
Evolus Evolus
EOLS
198 M $ 6.99 1.09 % $ 433 M usaUSA
Harrow Health Harrow Health
HROW
83.1 M $ 47.18 -7.67 % $ 1.54 B usaUSA
China Pharma Holdings China Pharma Holdings
CPHI
1.78 M $ 1.67 11.33 % $ 29.2 M chinaChina
OrganiGram Holdings OrganiGram Holdings
OGI
12.8 M $ 1.88 14.72 % $ 402 M canadaCanada
Lannett Company Lannett Company
LCI
81 M - 1.15 % $ 7.11 M usaUSA
Cumberland Pharmaceuticals Cumberland Pharmaceuticals
CPIX
11.1 M $ 2.61 4.99 % $ 36.7 M usaUSA
Neoleukin Therapeutics Neoleukin Therapeutics
NLTX
11.2 M - - $ 193 M canadaCanada
Organogenesis Holdings Organogenesis Holdings
ORGO
295 M $ 4.83 1.15 % $ 636 M usaUSA
Pacira BioSciences Pacira BioSciences
PCRX
294 M $ 26.28 2.14 % $ 1.22 B usaUSA
PetIQ PetIQ
PETQ
196 M - 1.64 % $ 400 M usaUSA
Relmada Therapeutics Relmada Therapeutics
RLMD
48.9 M $ 4.12 -1.67 % $ 124 M usaUSA
Jupiter Wellness Jupiter Wellness
JUPW
39.6 M - - $ 33.6 M usaUSA
Perrigo Company plc Perrigo Company plc
PRGO
468 M $ 13.13 -2.23 % $ 1.8 B usaUSA
ProPhase Labs ProPhase Labs
PRPH
34.4 M $ 0.12 -15.26 % $ 1.9 M usaUSA
Radius Health Radius Health
RDUS
131 M - - $ 1.42 B usaUSA
Recro Pharma Recro Pharma
REPH
21 M - -4.76 % $ 65.3 M usaUSA
Rockwell Medical Rockwell Medical
RMTI
12.1 M $ 0.93 -2.37 % $ 21.7 M usaUSA
Sundial Growers Sundial Growers
SNDL
38.4 M $ 2.19 24.01 % $ 3.37 M canadaCanada
OptiNose OptiNose
OPTN
79.8 M - - $ 1.08 B usaUSA
PLx Pharma PLx Pharma
PLXP
40 M - -27.8 % $ 2.56 M usaUSA
SCYNEXIS SCYNEXIS
SCYX
20.9 M $ 0.64 -0.02 % $ 30.6 M usaUSA
Solid Biosciences Solid Biosciences
SLDB
33.3 M $ 5.85 -0.34 % $ 239 M usaUSA
Sonoma Pharmaceuticals Sonoma Pharmaceuticals
SNOA
7.36 M $ 3.59 -3.37 % $ 4.46 M usaUSA
Tricida Tricida
TCDA
37.6 M - - $ 3.25 M usaUSA
Tilray Tilray
TLRY
165 M $ 11.86 40.68 % $ 7.33 B canadaCanada
TherapeuticsMD TherapeuticsMD
TXMD
8.9 M $ 1.79 -2.72 % $ 18.7 M usaUSA
Zomedica Corp. Zomedica Corp.
ZOM
29 M - -0.21 % $ 98 M usaUSA
Veru Veru
VERU
31.2 M $ 2.45 -4.3 % $ 330 M usaUSA
Viatris Viatris
VTRS
4.18 B $ 11.63 0.3 % $ 14.1 B usaUSA